CLL Coverage from Every Angle

Tait D. Shanafelt, MD, on Comparing Toxicities of New and Standard Treatments for CLL

Posted: Thursday, December 19, 2019

Tait D. Shanafelt, MD, of Stanford University, discusses the findings that although ibrutinib plus rituximab improves outcomes vs standard therapy in younger patients with previously untreated chronic lymphocytic leukemia, the new regimen is also associated with substantial adverse effects.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.